Baxter may stay out of Heparin business

Apr 25, 2008

The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

Baxter recalled vials of the drug two months ago after reports of allergic reactions. The U.S. Food and Drug Administration said the drug may have been intentionally contaminated with an animal-like substance to increase supplier profits.

The drug generates $30 million of Baxter's more than $11 billion in annual sales, the Chicago Tribune said Thursday. The newspaper said Wall Street analysts asked Chairman and Chief Executive Robert Parkinson last week if was worth the legal risks to remain in the heparin business.

"We haven't made a decision whether or not we are going to re-enter (the market) with heparin," Parkinson said.

Copyright 2008 by United Press International

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

'Killer sperm' prevents mating between worm species

44 minutes ago

The classic definition of a biological species is the ability to breed within its group, and the inability to breed outside it. For instance, breeding a horse and a donkey may result in a live mule offspring, ...

Full appeals court upholds labels on meat packages

56 minutes ago

(AP)—A federal appeals court has upheld new government rules that require labels on packaged steaks, ribs and other cuts of meat to say where the animals were born, raised and slaughtered.

Chinese smartphone makers win as market swells

56 minutes ago

Chinese smartphone makers racked up big gains as the global market for Internet-linked handsets grew to record levels in the second quarter, International Data Corp said Tuesday.

Connected devices have huge security holes: study

1 hour ago

The surge Web-connected devices—TVs, refrigerators, thermostats, door locks and more—has opened up huge opportunities for cyberattacks because of weak security, researchers said Thursday.

Recommended for you

FDA to start regulating lab-developed tests

3 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0